Current therapeutic advances, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 antibodies, have markedly improved the outcomes of patients with newly diagnosed MM (NDMM). This evidence concerns the gene CD38 and Miyoshi myopathy.